NASDAQ
EQRXW

EQRx Inc

Biotechnology
Healthcare

Prices are adjusted according to historical splits.

EQRx Inc Stock Price

Vitals

Today's Low:
$0.05
Today's High:
$0.0635
Open Price:
$0.0522
52W Low:
$0.1034
52W High:
$1.52
Prev. Close:
$0.0402
Volume:
2820

Company Statistics

Market Cap.:
$0
Book Value:
-8.18
Revenue TTM:
$0
Operating Margin TTM:
0%
Gross Profit TTM:
$0
Profit Margin:
0%
Return on Assets TTM:
0%
Return on Equity TTM:
0%

Company Profile

EQRx Inc had its IPO on 2021-12-21 under the ticker symbol EQRXW.

The company operates in the Healthcare sector and Biotechnology industry. EQRx Inc has a staff strength of 216 employees.

Stock update

Shares of EQRx Inc opened at $0.05 at the start of the last trading session i.e. 2023-09-12.

The stocks traded within a range of $0.05 - $0.06, and closed at $0.05.

This is a +24.38% increase from the previous day's closing price.

A total volume of 2,820 shares were traded at the close of the day’s session.

In the last one week, shares of EQRx Inc have increased by +20.48%.

EQRx Inc's Key Ratios

EQRx Inc has a market cap of $0, indicating a price to book ratio of 0 and a price to sales ratio of 0.

In the last 12-months EQRx Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-278076992. The EBITDA ratio measures EQRx Inc's overall financial performance and is widely used to measure its profitability.

In the trailing 12-month period, EQRx Inc’s operating margin was 0% while its return on assets stood at 0% with a return of equity of 0%.

In Q1, EQRx Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.

EQRx Inc’s PE and PEG Ratio

Forward PE
0
Trailing PE
0
PEG

Its diluted EPS in the last 12-months stands at $-7.653 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.

The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into EQRx Inc’s profitability.

EQRx Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0. Its price to sales ratio in the trailing 12-months stood at 0.

EQRx Inc stock pays annual dividends of $ per share, indicating a yield of 0% and a payout ratio of 0%.

Balance sheet and cash flow metrics

Total Assets
$1.38 billion
Total Liabilities
$59.88 million
Operating Cash Flow
$0
Capital Expenditure
$444000
Dividend Payout Ratio
0%

EQRx Inc ended 2024 with $1.38 billion in total assets and $0 in total liabilities. Its intangible assets were valued at $1.38 billion while shareholder equity stood at $1.31 billion.

EQRx Inc ended 2024 with $0 in deferred long-term liabilities, $59.88 million in other current liabilities, 49000.00 in common stock, $-610140000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $368.36 million and cash and short-term investments were $1.33 billion. The company’s total short-term debt was $2,368,000 while long-term debt stood at $0.

EQRx Inc’s total current assets stands at $1.35 billion while long-term investments were $4.00 million and short-term investments were $957.58 million. Its net receivables were $0 compared to accounts payable of $20.73 million and inventory worth $0.

In 2024, EQRx Inc's operating cash flow was $0 while its capital expenditure stood at $444000.

Comparatively, EQRx Inc paid $0 in dividends in 2024.

Other key metrics

Current Trading Price
$0.05
52-Week High
$1.52
52-Week Low
$0.1034
Analyst Target Price
$

EQRx Inc stock is currently trading at $0.05 per share. It touched a 52-week high of $1.52 and a 52-week low of $1.52. Analysts tracking the stock have a 12-month average target price of $.

Its 50-day moving average was $0.12 and 200-day moving average was $0.21 The short ratio stood at 0 indicating a short percent outstanding of 0%.

Around 0% of the company’s stock are held by insiders while 0% are held by institutions.

Frequently Asked Questions About EQRx Inc

The stock symbol (also called stock or share ticker) of EQRx Inc is EQRXW

The IPO of EQRx Inc took place on 2021-12-21

Similar Industry Stocks (Biotechnology)

Last Price
Chg
Chg%
$10.09
-0.08
-0.79%
$74.28
-0.1
-0.14%
$17.41
0.29
+1.69%
$306.95
-36
-10.5%
$65
-0.02
-0.03%
$0.25
-0
-1.03%
$0.1
-0.01
-8.18%
$31.41
-0.29
-0.91%

Most Active

Last Price
Chg
Chg%
Amyris Inc (AMRS)
$0.14
0.07
+100%
$0.12
0.04
+45.29%
$0.96
0.05
+5.4%
$1.34
-0.35
-20.71%
Humbl Inc (HMBL)
$0
0
0%

Top Gainers

Last Price
Chg
Chg%
$0
0
+172200%
$0
0
+51200%
$283
280.03
+9428.62%
$11.2
10.57
+1667.68%
Latch Inc (LTCHW)
$0.01
-0.03
+1550%

Top Losers

Last Price
Chg
Chg%
$0.19
-123.15
-99.85%
$0
-0.11
-99.55%
$0
-0
-97.96%
$0
-0.01
-93.94%
$0.01
-0.06
-92.24%

About

EQRx, Inc., a pharmaceutical company, engages in developing medicines primarily for the treatment of oncology and immune-inflammatory diseases in the United States. The company’s pre-registrational programs in Phase III clinical trial include Aumolertinib, an epidermal growth factor receptor (EGFR) inhibitor for the treatment of patients with EGFR-mutated non-small cell lung cancer (NSCLC); and Sugemalimab, an anti-programmed death-ligand 1 antibody for the treatment of Stage III and Stage IV NSCLC. Its other programs in pipeline include clinical and pre-clinical stage assets, which comprise Lerociclib, a small molecule cyclin-dependent kinase 4/6 inhibitor, which is in Phase I clinical trials in patients with metastatic breast cancer; EQ176, an anti-programmed death-1 antibody that is in Phase III trials for the treatment of patients with primary liver cancer; and EQ121, a selective janus kinase-1 inhibitor that is in various Phase I trials. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Address

50 Hampshire Street, Cambridge, MA, United States, 02139